Chang Yong Hu
Overview
Explore the profile of Chang Yong Hu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
92
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hu C, Yoon T
Biomater Res
. 2018 Dec;
22:33.
PMID: 30534414
Background: Total hip arthroplasty (THA) is probably one of the most successful surgical interventions performed in medicine. Through the revolution of hip arthroplasty by principles of low friction arthroplasty was...
2.
Chung J, Kim S, Jung S, Lee K, Seo H, Hu C, et al.
Asian Spine J
. 2013 Jan;
6(4):221-6.
PMID: 23275804
Study Design: Retrospective chart review. Purpose: To assess whether spontaneous reduction of spondylolisthesis, as seen on magnetic resonance imaging (MRI), is related to the degree of segmental instability and low...
3.
Jayaraman R, Pilla Reddy V, Pasha M, Wang H, Sangthongpitag K, Yeo P, et al.
Drug Metab Dispos
. 2011 Aug;
39(12):2219-32.
PMID: 21873472
The preclinical absorption, distribution, metabolism, and excretion (ADME) properties of Pracinostat [(2E)-3-[2-butyl-1-[2-(diethylamino) ethyl]-1H-benzimidazol-5-yl]-N-hydroxyarylamide hydrochloride; SB939], an orally active histone deacetylase inhibitor, were characterized and its human pharmacokinetics (PK) was predicted...
4.
Novotny-Diermayr V, Sangthongpitag K, Hu C, Wu X, Sausgruber N, Yeo P, et al.
Mol Cancer Ther
. 2010 Mar;
9(3):642-52.
PMID: 20197387
Although clinical responses in liquid tumors and certain lymphomas have been reported, the clinical efficacy of histone deacetylase inhibitors in solid tumors has been limited. This may be in part...